NEW YORK, NY – November 10, 2015 -- InvestorsHub NewsWire -- Small Cap Street makes the connection between sophisticated investors and high quality micro and small cap companies that are currently undervalued. We are an issuer of reports written by experienced financial analysts and who provide a straight forward assessment of a profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

*Feature Analyst Alert*

This week's NASDAQ alert is the lowest priced with the most upside potential that we have covered in a long time. Another reason we like this one so much their technology is proprietary. (NASDAQ: AMDA) is in the hot biotech / biomaterial space currently holding 56 patents issued and another 37 patents pending. As if that's not enough to get you excited, (NASDAQ: AMDA) has earnings due this week Thursday November 12th, 2015.

Earnings PR- http://finance.yahoo.com/news/amedica-corporation-release-third-quarter-201500678.html

Link to Amedica's Investor presentation at their website- http://investors.amedica.com/downloads.cfm

Link to Amedica's website providing information on the two analyst' that cover their securities Needham and JMP Securities - http://investors.amedica.com/analysts.cfm

Needham and JMP's targets are $1 and $3/share.

If you would like to receive profiles in real time, text "Street" to 25827

4 Brief Investor Updates

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials focused on the treatment of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.

The company just announced results from multiple new preclinical studies demonstrating enhanced anti-tumor activity and immune activation for combinations of a preclinical bavituximab (the PPHM lead immunotherapy candidate) equivalent and checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 in preclinical models of breast cancer and melanoma. Results from these studies were presented at the 2015 annual meeting of the Society for Immunotherapy of Cancer on November 4 - 8, 2015.

Amarin Corp. Plc (NASDAQ: AMRN) is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to an ongoing outcomes study. Amarin's first product, Vascepa® (icosapent ethyl) capsules, is a highly pure EPA omega-3 prescription product.

Key Amarin achievements since June 30, 2015 include: REDUCE-IT, study is progressing on schedule with enrollment now over 97% complete; Recognized $21.3 million in net product revenue from Vascepa® (icosapent ethyl) sales in Q3 2015 compared to $14.1 million in Q3 2014, an increase of 51%; Increased normalized prescriptions, based on data from Symphony Health Solutions, by 51% in Q3 2015 compared to Q3 2014.

RCS CAPITAL Corp. (NYSE: RCAP) is a full-service investment firm focused on the individual retail investor. RCS Capital's business is designed to capitalize, support, grow and maximize value for the investment programs it distributes and the independent advisors and clients it serves.

On November 9, 2015 the company announced the following changes: Completes $27 Million Issuance of New Senior Unsecured Promissory Notes to Provide Incremental Liquidity; $12 Million Issued to Affiliates of AR Capital, $15 Million Issued to Affiliates of Luxor Capital Group; Company and its Lenders Agree to Certain Modifications to Credit Facilities; Company Agrees to Sell Hatteras Liquid Alternatives Platform to the Hatteras Funds Management Group; Company Announces Changes to Board of Directors; Independent Board Members of RCS Capital Given Proxy to Vote Majority Class B Share and Series D-1 Preferred Shares; Company Given Right to Purchase B Share for $1.

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) is a biotechnology company developing immunotherapy products to treat cancers, without toxicities of the kind associated with chemotherapies.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM), which is on a partial clinical hold in regard to new screening of patients.
Last month the company raised $30 million with Woodford Investment Management in the UK. Woodford will purchase $30 million of the Company's common stock at $5.50 per share, for a total of 5,454,545 shares, raising Woodford's total holdings to 25,915,937 shares, or about 28.1% of the Company.  The purchase will take place in a closing on or before October 22, 2015.

With the new funding from Woodford the company will move its clinical programs for DCVax-L and DCVax-Direct ahead.

Forward-Looking Disclaimer   
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Compliance Procedure   
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and may make mistakes. This report was prepared for informational purposes only.  A full disclaimer can be found by viewing the full analyst report. We do not engage in high frequency trading or hold any positions of profiled company.

For more information and services provided beyond this release please use contact information provided below. If you notice any errors or omissions, please notify us below.

Source: Small Cap Street

Contact: editor@smallcapstreet.com
 

Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Avid Bioservices Charts.
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Avid Bioservices Charts.